Does Rheumatoid Arthritis Always Need Expensive Treatment?

Rheumatoid arthritis treatment has changed dramatically over the past two decades. Biologic medicines and newer targeted therapies have transformed the outlook for many people with severe or difficult-to-control disease.

But an important question patients increasingly ask is:

Does effective rheumatoid arthritis treatment always require expensive medication?

The short answer is no.

The goal of rheumatoid arthritis treatment is not to use the newest, strongest, or most expensive medicine. The goal is to control inflammation, prevent joint damage, preserve function, and achieve remission or low disease activity using the treatment that is appropriate for the individual patient.¹,²

At the same time, avoiding expensive treatment simply because of its cost would also be inappropriate. For some patients, biologic or targeted therapy can be exactly the treatment they need.

The principle is simple:

Use the treatment the patient needs—not more, and not less.

Starting with effective conventional treatment

For many patients with newly diagnosed rheumatoid arthritis, treatment begins with a conventional disease-modifying antirheumatic drug (DMARD), most commonly methotrexate.

Methotrexate has been used for decades, is relatively inexpensive, and remains a cornerstone of rheumatoid arthritis treatment.²

The American College of Rheumatology strongly recommends methotrexate monotherapy over starting a biologic or targeted synthetic DMARD in many treatment-naive patients with moderate-to-high disease activity. Cost is one of several considerations underlying these recommendations.¹

Being an older or less expensive medicine does not make a treatment inferior.

What matters is whether it controls the disease safely and effectively.

When should treatment be changed?

Rheumatoid arthritis should not simply be treated with a medication and then left unchanged indefinitely.

Modern rheumatology follows a treat-to-target approach.

This means assessing disease activity systematically and adjusting treatment when the patient is not progressing toward the agreed target, usually remission or low disease activity.²

The ACR strongly recommends a treat-to-target strategy for patients who have not previously received biologic or targeted synthetic DMARDs.¹

This also means recognizing two potential problems:

Overtreatment — escalating treatment when it is not clinically necessary.

Undertreatment — leaving active rheumatoid arthritis inadequately controlled simply to avoid a more advanced or expensive medication.

Neither represents good care.

When are biologic medicines appropriate?

Biologic medicines can be extremely effective and, for the right patient, potentially life-changing.

If rheumatoid arthritis remains active despite an appropriate conventional treatment strategy, escalation to biologic or targeted therapy may be justified.²,¹

The question should therefore not simply be:

"Can we avoid a biologic?"

Nor should it automatically be:

"Why haven't we started the newest treatment?"

A better question is:

"What treatment does my disease require at this point?"

Cost-conscious medicine should never mean withholding effective treatment when it is genuinely needed.

Does a more expensive medicine mean better treatment?

Not necessarily.

Different patients need different treatments.

A relatively inexpensive conventional medicine may control one patient's rheumatoid arthritis extremely well. Another patient may continue to have active inflammation and require biologic or targeted therapy.

The cost of a medicine by itself tells us little about whether it is the right medicine for an individual patient.

The ACR guideline illustrates this principle particularly well. It favors methotrexate monotherapy over initially combining methotrexate with a TNF inhibitor for many patients, noting that many will achieve their treatment goal with methotrexate alone and that immediately adding the biologic brings additional risks and costs.¹

This is not simply about choosing the cheapest medicine.

It is about value-based medical care: achieving the best appropriate clinical outcome without unnecessary treatment or burden.

Good treatment also means avoiding unnecessary investigations

Medication is only one component of the cost and burden of managing rheumatoid arthritis.

Repeated laboratory tests, imaging studies, procedures, consultations, and medication changes can all add cost and inconvenience.

Necessary investigations should never be avoided merely to save money. Laboratory monitoring, imaging, or other investigations may be important for diagnosis, assessing disease activity, monitoring medication safety, or investigating complications.

But every investigation should ideally have a purpose.

A useful question is:

"What will we do differently depending on the result of this test?"

If a test is unlikely to provide useful information or alter management, routinely repeating it may provide little value. The same reasoning applies when blood tests come back normal but the joints tell a different story.

Does rheumatoid arthritis need routine joint ultrasound monitoring?

Ultrasound is very good at detecting inflammation in joints and can sometimes identify synovitis that is not obvious on physical examination.³

That makes it valuable when there is a specific clinical question.

But detecting more abnormalities does not necessarily mean that routinely performing ultrasound—and escalating treatment to eliminate every ultrasound abnormality—improves patient outcomes.

This question has actually been tested in randomized clinical trials.

What did the ARCTIC trial find?

The ARCTIC randomized trial compared conventional tight-control rheumatoid arthritis treatment with a strategy that incorporated systematic ultrasound and targeted imaging remission.⁴

After two years, clinical remission and physical-function outcomes were similar between the groups.

Yet patients managed using the ultrasound strategy received more intensive treatment. At the end of the study, 29% were receiving biologic treatment compared with 17% in the conventional tight-control group, while only 53% remained on methotrexate monotherapy compared with 71% in the conventional group.⁴

In other words:

Finding more inflammation led to more treatment, but not clearly better overall outcomes.

What did the TaSER trial find?

A second randomized study, TaSER, reached a similar conclusion.

An ultrasound-driven treat-to-target strategy resulted in more intensive DMARD treatment, but this was not associated with significantly better overall clinical or imaging outcomes compared with conventional disease-activity-guided treatment.⁵

This is an important distinction.

It does not mean that ultrasound is unnecessary in rheumatoid arthritis.

Ultrasound can be very useful when:

• the physical examination is uncertain;
• symptoms and examination findings do not agree;
• a particular joint requires closer assessment;
• the clinician needs to distinguish inflammatory from other causes of symptoms;
• aspiration or injection needs image guidance.

What the evidence questions is routine ultrasound-driven escalation of treatment when good clinical treat-to-target assessment is already being performed.

Current EULAR imaging recommendations also caution against overinterpreting ultrasound abnormalities: sonographic abnormalities can occur in healthy individuals and other rheumatic diseases, and ultrasound-detected synovitis is not by itself diagnostic of rheumatoid arthritis.³

The same principle therefore applies to investigations as to medications:

A test should be performed when its result is likely to provide clinically useful information—not simply because the test can detect more abnormalities.

Cost should be part of shared decision-making

Patients sometimes hesitate to tell their doctor that a medication, investigation, or treatment plan is financially difficult.

They should feel comfortable doing so.

Rheumatoid arthritis is usually a long-term condition. Affordability can affect whether a treatment plan remains sustainable.

Treatment decisions should consider disease activity and prognosis alongside safety, other medical conditions, patient preferences, practical circumstances, and the burden of treatment.²

Sometimes there are equally reasonable alternatives with substantially different costs.

Sometimes there are not.

The important thing is to have the conversation rather than stopping or reducing medication without medical advice.

What does efficient rheumatoid arthritis care mean?

Efficient medical care does not mean choosing the cheapest treatment or performing the fewest investigations.

It means trying to achieve the best appropriate clinical outcome while avoiding interventions that are unlikely to benefit the patient.

Sometimes that means continuing an inexpensive conventional DMARD that is working well.

Sometimes it means optimizing methotrexate before abandoning it. The ACR guideline, for example, recommends considering strategies such as switching oral methotrexate to subcutaneous administration before moving to alternative DMARDs in appropriate patients who are not at target.¹

Sometimes it means deciding that another ultrasound is unlikely to change management.

And sometimes it means moving decisively to an expensive biologic or targeted therapy because persistent inflammatory disease poses a greater risk than the cost of treatment.

Doing more is not automatically better medicine. Doing less is not automatically better medicine either.

The objective is to do what is necessary for that patient. This is the same reasoning behind how I choose the right treatment for any rheumatic disease.

Frequently Asked Questions

Can rheumatoid arthritis be treated without biologics?

Yes. Many patients can achieve good disease control with conventional DMARDs. Others require biologic or targeted therapy. Treatment should depend on disease activity, response to previous therapy, prognosis, safety considerations, and individual circumstances.

Is methotrexate still an effective treatment for rheumatoid arthritis?

Yes. Methotrexate remains an important anchor treatment for rheumatoid arthritis and is recommended as initial therapy for many patients with moderate-to-high disease activity.

When should a biologic be considered?

Biologic or targeted therapy may be appropriate when disease remains inadequately controlled despite an appropriate conventional treatment strategy. The decision should be individualized rather than based simply on how new or expensive a medication is.

Are expensive rheumatoid arthritis medicines better?

Not automatically. More expensive treatments can be extremely effective and necessary for some patients, but expense itself does not make a medicine more appropriate. The objective is to choose treatment according to clinical need, effectiveness, safety, and the patient's circumstances.

Does every rheumatoid arthritis patient need regular joint ultrasound?

No. Ultrasound can be very useful for specific clinical questions, but randomized trials have not demonstrated that routinely using ultrasound to drive treatment escalation provides clearly superior overall outcomes compared with good clinical treat-to-target management.

Can ultrasound lead to overtreatment in rheumatoid arthritis?

Potentially. In the ARCTIC trial, systematic ultrasound-guided management resulted in greater use of biologic treatment without significantly better overall clinical outcomes. This does not mean ultrasound should be avoided; rather, it supports using ultrasound when it is likely to answer a meaningful clinical question.

Should I tell my rheumatologist if my treatment is becoming too expensive?

Yes. Financial burden is a reasonable part of shared decision-making. Patients should not stop or reduce rheumatoid arthritis medication themselves because of cost; possible alternatives should first be discussed with their rheumatologist.

A thoughtful approach to rheumatoid arthritis treatment

At Health Call Clinic, our approach can be summarized in one principle:

Use the treatment the patient needs—not more, and not less.

Treatment decisions should be guided by evidence, disease activity, safety, and the individual patient's circumstances.

Newer and more expensive treatments can be invaluable when clinically appropriate. Advanced investigations can also provide important information when they answer a meaningful clinical question.

But more medication, more testing, and more intervention do not automatically mean better medical care.

The objective is effective disease control while minimizing unnecessary treatment, risk, investigations, and burden on the patient.

If you would like an assessment or a second opinion on your current treatment plan, you can book a rheumatology consultation or read more about rheumatoid arthritis care in Dubai.

This article provides general educational information and is not a substitute for an individualized assessment, diagnosis, or treatment plan. Do not stop or change rheumatoid arthritis medication without discussing it with your rheumatologist.